https://www.roche.ch/en/sites/schlieren  

8952 Schlieren, Wagistrasse 10

 +41 43 215 10 00

The mission of the Roche Innovation Center Zurich (RICZ) is to be a leader in developing new generations of engineered antibody products with increased efficacy that address unmet clinical needs. The RICZ site is also the Center of Excellence in Cancer Immunotherapy within the Roche Group.

https://www.campus-schlieren.uzh.ch/en.html  

8952 Schlieren, Wagistrasse 12

The University of Zurich (UZH) is Switzerland’s largest university, with seven faculties and a current enrollment of over 26,000 students. More than 5,000 highly qualified members of the teaching staff, including some 580 professors, teach and conduct research at the 150 University institutes. In the field of life sciences, the University of Zurich is well known for its groundbreaking research in medicine, immunology, neuroscience, and structural biology. In the interest of serving the community, the University of Zurich promotes the transfer of research-based knowledge to private enterprise, and our spin-off ventures and business partnerships regularly lead to the creation of attractive jobs in innovative fields.

https://ethz.ch/en/industry/entrepreneurship.html  

8952 Schlieren, Wagistrasse 18

 entrepreneurship@ethz.ch

Excellence in entrepreneurship at ETH Zurich is driven by world-​class research and education. It gives rise to groundbreaking new ventures that consolidate Switzerland’s technological leadership. Are you an aspiring entrepreneur seeking to find solutions to global challenges and create a better future for humanity. Or are you just interested in the entrepreneurial ecosystem at ETH Zurich? Browse our websites to find out more or reach out to the Entrepreneurship group, if you have any questions. 

https://www.wysszurich.ch/projects/somagenetix  

8952 Schlieren, Wagistrasse 23

Gene therapy solutions for patients with severe inherited diseases.

https://www.exyte.net/switzerland  

8952 Schlieren, Wagistrasse 6 / Exyte Switzerland (Zurich)

 +41 43 3118585
 info.ch@exyte.net

Process plants, infrastructural facilities and buildings for the life sciences industries: Turnkey design and construction of future-oriented facilities starts with a profound concept design. For more than 15 years, Exyte has established ourselves in Switzerland with two offices, in Schlieren (near Zurich) and Muttenz (next to Basel), where we feature solutions and services through the lifecycle of complex production facilities. Our unique expertise combines seamless project execution, including consulting, planning, design, and construction, as well as commissioning and operation with a high level of professionalism, knowledge, and competence over all disciplines. These include process, infrastructure, construction and operation of life science production plants.

http://www.bio-technopark.ch/  

8952 Schlieren, Wagistrasse 23

 +41 76 336 99 44
 mario.jenni@bio-technopark.ch

The Bio-Technopark offers professional support for life science start-ups in the setting up and expansion of business activities and promotes interaction between start-ups, academia and industry. A nationally and internationally respected science park has grown up at Schlieren. Through stringent selection, coaching and support, more than 30 successful start-up companies with 750 employees are located here. Eight have been acquired by large corporates, but are still active in the park. Together with 20 institutes and clinics from the University and University Hospital Zurich, an innovative mix of very young and well-established companies and academic research groups has emerged.

https://www.stadt-zuerich.ch/prd/de/index/stadtentwicklung/wirtschaftsfoerderung.html  

8001 Zürich, Stadthaus

The City of Zurich is committed to a sustainable urban and economic development and offers an attractive business environment for established and new companies alike. We foster Zurich's function a as dense knowledge center where companies, startups, research facilities, universities and technical colleges are in close proximity and are able to network and exchange ideas and new business opportunities easily. We facilitate a continuous dialogue between policymakers and the business community and support new companies in establishing the necessary connections to succeed in the diverse Zurich business ecosystem. Our BlueLion incubator offers an acceleration program for startups focusing on Climate Tech and Digital Health. #EconomicDevelopment #BioTechnopark #Zurich #Innovation #Sustainability

https://ghzschlieren.ch/  

8952 Schlieren, Wagistrasse 23

 +41 44 730 83 21
 info@ghzschlieren.ch

The Wagiareal in Schlieren has undergone major construction in recent years. Successful companies in the biotech, communications and administration sectors have established themselves in recent years. The excellently developed real estate optimally supports the companies in achieving their goals. In the future, new office and commercial space for trade, commerce and manufacturing will be created on an ongoing basis. The new projects are being developed in connection with and with synergies of the existing properties. They allow for individual rental space in various sizes, locations and fit-out standards. Not only will you receive suitable space according to your requirements, but we will also take into account your expansion wishes and expansion options. possibilities. Expansion financing, fair rental prices, uncomplicated contract processing and an open ear for our tenants are a matter of course for us.

https://dinaqor.com/  

8952 Schlieren, Wagistrasse 25

DiNAQOR’s mission is to develop gene therapy solutions that transform the lives of patients with heart disease. Our novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure.

http://www.novagotherapeutics.com  

8952 Schlieren, Wagistrasse 27

 info@novagotherapeutics.com

NovaGo Therapeutics is a biotech start-up company dedicated to the development of human antibody therapeutics that promote nerve repair and regeneration in the treatment of cerebral stroke and spinal cord injury. NovaGo is developing human antibody therapeutics against Nogo-A. Nogo-A is the most potent inhibitor of nerve fiber regeneration. Anti-NogoA treatment promotes recovery of function in several animal models of stroke. Novago Therapeutics' anti-NogoA treatment represents a novel, regenerative approach for stroke. Recovery of function in stroke and other neurological disorders will be a clinical breakthrough and have a major economic impact on health care.